Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This multiple-center, nonrandomized, open label, parallel group, single dose study will be
conducted in male and female subjects with normal renal function or severe (eGFR <30
mL/min/1.73 m2) renal impairment to evaluate the effect of renal impairment on the
pharmacokinetics (PK) of TD 4208.